Maryland is currently home to 2690 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
REFINE Study: A Study In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
NCT05504499
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of the use of Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material in fusion in patients with chronic low back pain that present with degenerative disc disease with concurrent neurogenic claudication.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2022
Locations: National Spine and Pain Centers, Oxon Hill, Maryland
Conditions: Lumbar Spinal Stenosis
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: American Oncology Partners of Maryland, PA, Bethesda, Maryland
Conditions: Breast Cancer
Register for Updates
Clinical Care Consortium of Telomere-Associated Ailments (CCCTAA) Database
NCT05436431
Recruiting
Study Description: This protocol will be utilized for the creation and management of a repository of coded clinical data on patients with Telomere Biology Disorders (TBDs) submitted by researchers from CCCTAA member institutions. Objective: The primary objective of this study is to develop a shared database (repository) of coded clinical research data, managed by NCI, to facilitate collaborative research across CCCTAA member institutions.
Gender:
All
Ages:
All
Trial Updated:
07/12/2022
Locations: NIH National Cancer Institute - Shady Grove, Rockville, Maryland
Conditions: Telomere Biology Disorders, Dyskeratosis Congenita, Inherited Bone Marrow Failure Syndrome
Register for Updates
Kidney Precision Medicine Project
NCT04334707
Recruiting
Acute kidney injury (AKI) and chronic kidney disease (CKD) impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. Despite significant effort from industry and academia, development of pharmacologic therapies for AKI and CKD has been hampered by: Non-predictive animal models The inability to identify and prioritize human targets The limited availability of human kidney biopsy tissue A poor understanding of AKI and CK... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2022
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic
Register for Updates
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT05211856
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Baltimore, Maryland
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Transplants With Unlicensed Preserved Cord Blood
NCT01553461
Recruiting
Background: - Cord blood transplants can treat cancers and other diseases in children and adults. The U.S. Food and Drug Administration (FDA) requires cord blood to be collected and stored under certain safety standards. However, most available cord blood units were collected before the FDA set these standards. These units may not meet FDA standards, but they do meet similar standards set and followed by the National Marrow Donor Program (NMDP). Cord blood units that do not meet the new FDA sta... Read More
Gender:
All
Ages:
Between 4 years and 99 years
Trial Updated:
10/07/2021
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Myelodysplastic Syndrome (MDS), Hematologic Neoplasms, Hematologic Diseases, Severe Aplastic Anemia
Register for Updates
Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04363502
Recruiting
In this study Investigators propose to administer clazakizumab to patients with life-threatening COVID-19 infection manifest by pulmonary failure and a clinical picture consistent with a cytokine storm syndrome. This is a single-center randomized, double-blind, placebo-controlled trial in which 30 patients will be enrolled and randomly assigned in a 1:1 ratio to two study arms that will receive clazakizumab at a dose of 25 mg or placebo.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/10/2021
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Covid19
Register for Updates
A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004
NCT04768452
Recruiting
This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single dose of MT2004 following oral single and multiple ascending dose administration.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/20/2021
Locations: Pharmaron CPC, Baltimore, Maryland
Conditions: Healthy
Register for Updates
Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
NCT03609398
Recruiting
This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/10/2021
Locations: Special Immunization Program, Division of Medicine, USAMRIID, Fort Deterick, Maryland
Conditions: Rift Valley Fever
Register for Updates
Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
NCT04692662
Recruiting
Background: People with advanced cancer are usually treated with surgery, radiation, immunotherapy drugs, or chemotherapy drugs. Talazoparib is a type of drug called a PARP inhibitor. It prevents DNA repair and has shown anticancer activity in early clinical trials. Researchers want to learn more about how it works in different types of patients. Objective: To find out how talazoparib works in tumor cells and if it works differently in people who have or have not already been treated with ano... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2021
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Solid Tumors
Register for Updates
Spinal Cord Injury Registry - North American Clinical Trials Network
NCT00178724
Recruiting
The NACTN Spinal Cord Injury Registry is a network of clinical centers collecting de-identified data from patients admitted through the Emergency Department of a NACTN center at the time of injury with an initial (first time) spinal cord injury (SCI). Information will be collected on the natural history of SCI and course of treatment through the first 12 months from the date of injury or long as medically indicated. Data collected includes imaging information from CT or MRI scans, neurological a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/22/2020
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Spinal Cord Injury
Register for Updates
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
NCT04519099
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: CBH Health LLC, Gaithersburg, Maryland
Conditions: Schizophrenia
Register for Updates